CA2920173C - Antibody binding sites specific for egfrviii - Google Patents

Antibody binding sites specific for egfrviii Download PDF

Info

Publication number
CA2920173C
CA2920173C CA2920173A CA2920173A CA2920173C CA 2920173 C CA2920173 C CA 2920173C CA 2920173 A CA2920173 A CA 2920173A CA 2920173 A CA2920173 A CA 2920173A CA 2920173 C CA2920173 C CA 2920173C
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
egfrviii
chain domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2920173A
Other languages
English (en)
French (fr)
Other versions
CA2920173A1 (en
Inventor
Kristina Ellwanger
Uwe Reusch
Ivica FUCEK
Stefan Knackmuss
Vera MOLKENTHIN
Melvyn Little
Eugene ZHUKOVKSY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics AG filed Critical Affimed Therapeutics AG
Publication of CA2920173A1 publication Critical patent/CA2920173A1/en
Application granted granted Critical
Publication of CA2920173C publication Critical patent/CA2920173C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2920173A 2013-08-07 2014-08-07 Antibody binding sites specific for egfrviii Active CA2920173C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13179630 2013-08-07
EP13179630.2 2013-08-07
EP13189599 2013-10-21
EP13189599.7 2013-10-21
PCT/EP2014/002177 WO2015018527A1 (en) 2013-08-07 2014-08-07 ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII

Publications (2)

Publication Number Publication Date
CA2920173A1 CA2920173A1 (en) 2015-02-12
CA2920173C true CA2920173C (en) 2021-08-10

Family

ID=51453717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2920173A Active CA2920173C (en) 2013-08-07 2014-08-07 Antibody binding sites specific for egfrviii

Country Status (13)

Country Link
US (1) US10273309B2 (enExample)
EP (1) EP3030581B1 (enExample)
JP (1) JP6529498B2 (enExample)
CN (1) CN105555804B (enExample)
AU (1) AU2014304930B2 (enExample)
CA (1) CA2920173C (enExample)
DK (1) DK3030581T3 (enExample)
HR (1) HRP20210561T1 (enExample)
HU (1) HUE054057T2 (enExample)
LT (1) LT3030581T (enExample)
RU (1) RU2696892C2 (enExample)
SI (1) SI3030581T1 (enExample)
WO (1) WO2015018527A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY178160A (en) * 2014-03-11 2020-10-06 Regeneron Pharma Anti-egfrviii antibodies and uses thereof
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CN107108735B (zh) * 2014-11-25 2021-05-04 药物抗体公司 新型egfrviii抗体和包含所述抗体的组合物
EP4190814A1 (en) 2015-05-29 2023-06-07 Amphivena Therapeutics, Inc. Methods of using bispecific cd33 and cd3 binding proteins
EP3307319A4 (en) 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA
WO2016204966A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EP3405481B1 (en) 2016-01-21 2023-01-18 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
CN109219618B (zh) * 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
CN107556386A (zh) * 2016-06-30 2018-01-09 中国科学院深圳先进技术研究院 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用
RU2721582C1 (ru) * 2016-08-05 2020-05-20 И-Байолоджикс Инк. Антитела против лиганда-1 запрограммированной смерти (PD-L1) и их применение
AU2017306506B2 (en) 2016-08-05 2020-05-21 Y-Biologics Inc. Antibody to programmed cell death 1 (PD-1) and use thereof
CN106501518A (zh) * 2017-01-06 2017-03-15 北京弘润天源生物技术股份有限公司 一种检测EGFRvⅢ的免疫组化抗体试剂及检测方法
CA3051062C (en) * 2017-02-28 2023-09-26 Affimed Gmbh Tandem diabody for cd16a-directed nk-cell engagement
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
KR102924742B1 (ko) * 2018-03-14 2026-02-10 아피메트 게엠베하 이중특이적 egfr/cd16 항원-결합 단백질
CN118271445A (zh) * 2018-12-21 2024-07-02 豪夫迈·罗氏有限公司 与cd3结合的抗体
AU2020208110A1 (en) * 2019-01-14 2021-07-15 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
WO2022002033A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 具有H2L2与HCAb结构的结合蛋白
US20240101646A1 (en) * 2021-01-22 2024-03-28 Vanderbilt University Sars-cov-2 coronavirus antibodies and uses thereof
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
EP4370557A4 (en) * 2021-07-16 2025-10-01 Medical Guidance Systems Llc TAX-INTERACTING PROTEIN-BINDING MOLECULES 1 (TIP1)
CN116375868A (zh) * 2021-12-31 2023-07-04 康源博创生物科技(北京)有限公司 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用
TW202506733A (zh) 2023-06-12 2025-02-16 美商安進公司 淋巴毒素β受體促效劑結合蛋白

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
PL357448A1 (en) * 2000-02-25 2004-07-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Anti-egfrviii scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7736644B2 (en) * 2003-06-27 2010-06-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof

Also Published As

Publication number Publication date
CN105555804A (zh) 2016-05-04
EP3030581B1 (en) 2021-01-20
AU2014304930A1 (en) 2016-02-25
HK1218552A1 (zh) 2017-02-24
EP3030581A1 (en) 2016-06-15
HUE054057T2 (hu) 2021-08-30
RU2696892C2 (ru) 2019-08-07
CA2920173A1 (en) 2015-02-12
JP2016536322A (ja) 2016-11-24
BR112016002610A2 (pt) 2017-09-12
CN105555804B (zh) 2020-12-25
AU2014304930B2 (en) 2019-11-21
HRP20210561T1 (hr) 2021-05-14
US20160152728A1 (en) 2016-06-02
BR112016002610A8 (pt) 2018-01-23
RU2016106577A (ru) 2017-09-14
DK3030581T3 (da) 2021-04-12
SI3030581T1 (sl) 2021-07-30
JP6529498B2 (ja) 2019-06-12
LT3030581T (lt) 2021-05-25
WO2015018527A1 (en) 2015-02-12
US10273309B2 (en) 2019-04-30

Similar Documents

Publication Publication Date Title
US10273309B2 (en) Antibody binding sites specific for EGFRvIII
JP6879998B2 (ja) Ｃｄ７０及びｃｄ３に対する抗体構築物
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
KR101838786B1 (ko) 성장 및 분화 인자 15 (gdf-15)에 대한 모노클로날 항체
JP2020147599A (ja) 二重特異性ｃｄ３３およびｃｄ３結合タンパク質
JP2017520575A (ja) 二重特異的ヘテロ二量体ダイアボディおよびその使用
EA039594B1 (ru) Биспецифические конструкции антител к bcma и cd3, вовлекающие т-клетки
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
KR20180014066A (ko) 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
CN117916263B (zh) 抗tigit抗体及其用途
KR20230169944A (ko) Mage-a4 펩티드-mhc 항원 결합 단백질
JP2023526977A (ja) Ｃｄ４０結合タンパク質
EP4304725A1 (en) Rabbit-derived antigen binding protein nucleic acid libraries
KR20230074192A (ko) 인간 cd3 엡실론에 결합하는 신규의 인간 항체
US20230046744A1 (en) Methods and means for attracting immune effector cells to tumor cells
CN113727731B (zh) 靶向pd-1和lag-3的双特异性抗体
JP2025534237A (ja) Ｍａｇｅ－ａ４ペプチドデュアルｔ細胞エンゲージャー
US20260116983A1 (en) Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use
JP7858057B2 (ja) Ｃｄ９４／ｎｋｇ２ａヘテロ二量体ポリペプチドに結合する分子
KR20240006506A (ko) 항-백시니아 바이러스 항원 항체 및 관련 조성물 및 방법
HK1218552B (zh) 对egfrviii有特异性的抗体结合位点
BR112016002610B1 (pt) Anticorpo de ligação a locais específicos para egfrviii
TW202544039A (zh) 對ｃｄ４７和ｐｄｌ１具有特異性的多特異性抗體、編碼其之核酸、包含其之醫藥組合物、對應其之抗體結合域、包含對應其之抗體結合域之抗體及包含編碼其之核酸的宿主細胞
HK40038005B (zh) 用於肿瘤特异性细胞清除的抗-cd25
HK40036205B (zh) 用於肿瘤特异性细胞清除的抗-cd25

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170613

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240729

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250730